Cempra Pharmaceuticals makes board appointment
This article was originally published in Scrip
Executive Summary
Cempra Pharmaceuticals (US) has appointed John Johnson, CEO of ImClone Systems, to its board of directors. Cempra is a clinical-stage biotechnology company developing two antibacterials – CEM-101 and CEM-102.